Astria Therapeutics Inc (NASDAQ:ATXS) — Market Cap & Net Worth
Market Cap & Net Worth: Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc (NASDAQ:ATXS) has a market capitalization of $718.13 Million ($718.13 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10709 globally and #2651 in its home market, demonstrating a 47002.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Astria Therapeutics Inc's stock price $5873.65 by its total outstanding shares 57084838 (57.08 Million). Analyse ATXS cash flow metrics to see how efficiently the company converts income to cash.
Astria Therapeutics Inc Market Cap History: 2015 to 2026
Astria Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $27.16 Billion to $335.30 Billion (26.53% CAGR).
Index Memberships
Astria Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.03% | #287 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1055 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.04% | #171 of 263 |
Weight: Astria Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Astria Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Astria Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10206.77x
Astria Therapeutics Inc's market cap is 10206.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $5.10 Billion | $500.00K | -$27.36 Million | 10206.77x | N/A |
Competitor Companies of ATXS by Market Capitalization
Companies near Astria Therapeutics Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Astria Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Astria Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Astria Therapeutics Inc's market cap moved from $27.16 Billion to $ 335.30 Billion, with a yearly change of 26.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $335.30 Billion | +44771.28% |
| 2025 | $747.24 Million | +46.42% |
| 2024 | $510.34 Million | +16.41% |
| 2023 | $438.41 Million | -48.42% |
| 2022 | $849.99 Million | +176.25% |
| 2021 | $307.69 Million | -58.02% |
| 2020 | $732.97 Million | -63.79% |
| 2019 | $2.02 Billion | +35.24% |
| 2018 | $1.50 Billion | -70.67% |
| 2017 | $5.10 Billion | -58.73% |
| 2016 | $12.36 Billion | -54.48% |
| 2015 | $27.16 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Astria Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $718.13 Million USD |
| MoneyControl | $718.13 Million USD |
| MarketWatch | $718.13 Million USD |
| marketcap.company | $718.13 Million USD |
| Reuters | $718.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more